Cargando…

Hepatic arterial infusion of oxaliplatin plus raltitrexed in unresectable hepatocellular carcinoma with or without portal vein tumour thrombosis

BACKGROUND: Unresectable hepatocellular carcinoma (HCC) has a poor prognosis. According to the HCC management guidelines in China, the standard treatment of Barcelona Clinic Liver Cancer (BCLC) stage B or C HCC with portal vein tumour thrombosis (PVTT) is chemoembolization. However, some patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Shiguang, Yu, Wenchang, Zhang, Kongzhi, Liu, Weifu, Wang, Xiaolong, Chen, Chuanben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106995/ https://www.ncbi.nlm.nih.gov/pubmed/35582475 http://dx.doi.org/10.1093/gastro/goac016

Ejemplares similares

Transarterial chemoembolization for unresectable hepatocellular carcinoma: A comparison of the efficacy and safety of 2 embolic agents
por: Chen, Shiguang, et al.
Publicado: (2018)

A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases
por: Feng, Ai-Wei, et al.
Publicado: (2022)

Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
por: Shao, Wenbo, et al.
Publicado: (2019)

Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin
por: Cui, Wei, et al.
Publicado: (2017)

Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Liu, Baojiang, et al.
Publicado: (2019)

Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma
por: Chen, Shiguang, et al.
Publicado: (2018)

Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus
por: Zhu, Lin-Zhong, et al.
Publicado: (2018)

Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization
por: Wu, Yanfang, et al.
Publicado: (2022)

Conversion Therapy of Large Unresectable Hepatocellular Carcinoma With Ipsilateral Portal Vein Tumor Thrombus Using Portal Vein Embolization Plus Transcatheter Arterial Chemoembolization
por: He, Chengjian, et al.
Publicado: (2022)

Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer
por: Feliu, J, et al.
Publicado: (2005)

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
por: Ulrich-Pur, H, et al.
Publicado: (2003)

Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients
por: Comella, P, et al.
Publicado: (2002)

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
por: Gravalos, Cristina, et al.
Publicado: (2012)

Portal Vein Thrombosis
por: Cohen, Ronny, et al.
Publicado: (2015)

Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis
por: Guo, Jian-Hai, et al.
Publicado: (2017)

Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma
por: Bi, Yonghua, et al.
Publicado: (2023)

Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis
por: Lee, Sung Won, et al.
Publicado: (2017)

Melioidosis with Portal Vein Thrombosis
por: Direksunthorn, Thanyaporn
Publicado: (2017)

TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
por: Yang, Biao, et al.
Publicado: (2021)

Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Tertiary Care Center Experience
por: Patidar, Yashwant, et al.
Publicado: (2021)

Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma
por: Chen, Haoqi, et al.
Publicado: (2022)

Hepatic Arterial Infusion Oxaliplatin Plus Oral S-1 Chemotherapy in Gastric Cancer with Unresectable Liver Metastases: A Case Series and Literature Review
por: Wang, Kangxin, et al.
Publicado: (2020)

Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
por: Liu, Min, et al.
Publicado: (2020)

Spontaneous Resolution of Portal Vein Thrombosis
por: Banumukala, Vishnu, et al.
Publicado: (2008)

Etiology and Complications of Portal Vein Thrombosis
por: Trebicka, Jonel, et al.
Publicado: (2014)

Management of Portal/Mesenteric Vein Thrombosis
por: Kalff, Jörg C., et al.
Publicado: (2014)

Idiopathic Thrombosis of the Portal and Contributory Veins
por: Rogers, Bertram M. H.
Publicado: (1899)

Portal vein thrombosis in patients with cirrhosis
por: von Köckritz, Leona, et al.
Publicado: (2017)

Insulin Resistance and Portal Vein Thrombosis
por: Aung, Nay Linn, et al.
Publicado: (2019)

Increased portal vein diameter is predictive of portal vein thrombosis development in patients with liver cirrhosis
por: Dong, Gang, et al.
Publicado: (2021)

Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study
por: Chen, Song, et al.
Publicado: (2023)

Portal Vein Thrombosis in Unresectable Hcc Cases: a Single Center Study of Prognostic Factors and Management in 140 Patients
por: Abdelmaksoud, Ahmed Hosni, et al.
Publicado: (2017)

S‐1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial
por: Chen, Ye, et al.
Publicado: (2019)

A Multicenter Phase II Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer
por: Woo, Sang Myung, et al.
Publicado: (2013)

Cavernous Transformation of Portal Vein Secondary to Portal Vein Thrombosis: A Case Report
por: Ramos, Radhames, et al.
Publicado: (2012)

A Large Portal Vein: A Rare Finding of Recent Portal Vein Thrombosis
por: Qi, Xingshun, et al.
Publicado: (2011)

Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma
por: Bi, Yonghua, et al.
Publicado: (2022)

One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma
por: Lai, Zhicheng, et al.
Publicado: (2022)

A Case of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Treated by Hepatic Arterial Infusion Chemotherapy and Radiotherapy
por: Lee, Jin Yong, et al.
Publicado: (2020)

Liver Transplantation in the Presence of Portal Vein Thrombosis
por: McMaster, Paul
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_1hlrvqdk7ulb8km7lsm4e6rm25